I congratulate Yeung and colleagues\(^1\) for their development of an elegant, sophisticated, and innovative technology and also commend their collaboration across multiple disciplines and institutions. The basic concept they propose is intuitively very appealing—use patient-specific anatomy, guided by computational fluid dynamics, to develop 3-dimensional (3D) vascular grafts tailored to a given patient’s specific needs—in this particular case, the creation of bifurcated pulmonary artery grafts. The reader should look beyond the fact that both animals originally had normal anatomy, as I presume the computer-aided design phase would permit creation of any desired anatomy (for missing parts), which could then be modified to fit the patient’s true anatomy. Computational fluid dynamics would then refine the model for function and subsequent 3D printing, mandrel formation, and electrospinning to create the graft.

The combination of 3D printing and electrospinning represents a newer generation of decades of effort in the field of tissue engineering and has incredible implications for replacing diseased or missing parts of anatomy. However, an enormity of variables complicate engineering blood vessels.\(^2\) Of the few reports in humans using tissue-engineered grafts predominantly for the Fontan procedure, Sugiuira and others\(^3-5\) have reported the longest-term follow-up. At 11 years, 28% of patients had undergone angioplasty for graft stenosis.\(^6\) The only other in-human application has been for arteriovenous fistulae for dialysis access with 1-year primary patency rates of approximately 30%.\(^6\) A recent study in immunodeficient mice offers some sobering, instructive insight.\(^7\) The authors compared 3-mm length grafts placed in the intra-abdominal aorta and inferior vena cava and examined them throughout the period required for resorption of the polymer. Grafts in the inferior vena cava performed very well, whereas all grafts in the intra-abdominal aorta failed due to aneurysm formation and rupture. In their review of the literature, the authors comment that there has yet to be a report of an electrospun graft fully degrading and remodeling into a functional neo-vessel in vivo.

With regard to the present report and an anticipated resorption period of 6 months for the polymer, 2 animals and 1 month of follow-up prove nothing other than demonstration of concept. In fact, the notable increase in compliance at 1 month may presage vulnerability to aneurysm formation in a pulsatile vascular bed with systolic pressure considerably greater than what exists in the Fontan circulation. Even a suggestion of durable and safe function will require a larger animal study with much longer follow-up—not an easy task. For now, we can offer encouragement and be grateful that talented individuals such as these authors are developing and testing innovative technology to help congenital heart surgery patients.

**Central Message**

An assessment of the potential utility of tissue-engineered vascular grafts requires longer-term follow-up.

**See Article page 1971.**

---

**References**
